14 citations
,
January 2020 in “Mediterranean Journal of Rheumatology” New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
1 citations
,
October 2021 in “Bioactive compounds in health and disease” Hibiscus anthocyanins help protect the liver and improve antioxidants in diabetic rats.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
6 citations
,
October 2014 in “International Journal of Molecular Sciences” Tanshinone IIA helps protect tissue from low oxygen damage by activating certain cell pathways.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
June 2025 in “Experimental and Сlinical Urology” Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
January 2015 in “Elsevier eBooks” Nanocarriers like liposomes and cyclodextrins improve how angiotensin-(1-7) is delivered in the body.
February 2026 in “Advanced Science” TTNPB helps turn stem cells into neural stem cells, improving depression-like behaviors in rats.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
4 citations
,
March 2007 in “British Journal of Dermatology” Gefitinib therapy can cause unusual hair growth on the nose.
June 2026 in “International Journal of Drug Delivery Technology” Fast-dissolving nifedipine tablets were successfully developed for better oral delivery.
20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
211 citations
,
May 2013 in “Journal of Nutrition Health & Aging” MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.